Objective-To estimate the prevalence of important side effects in patients with malignant disease who were receiving high doses of morphine as part of their palliative treatment.
Setting-Two palliative care units in Western Australia.
Patients- 19 Patients with malignant disease who were receiving morphine either subcutaneously or orally as the main analgesic. 10 Patients receiving a total daily dose of morphine of at least 500 mg orally or 250mg parenterally were enrolled in the study. The other 9 patients were enrolled after an important problem thought to be related to the morphine had been identified. All of the patients were taking drugs to supplement the treatment.
Interventions-The dose of morphine or route of administration, or both, was changed in three patients.
Main outcome measure-Determination of the prevalence ofside effects in the patients. Assessment of the relation of any side effects with the supplemental drugs taken by the patients.
Main results-Plasma morphine and electrolyte concentrations were measured and a full history taken for each patient. Thirteen of the 19 patients had an important side effect; 12 of them had myoclonus and one had hyperalgesia of the skin. Plasma morphine concentrations were similar in patients with and without myoclonus, ranging from 158 to 3465 nmol/l and 39 to 2821 nmol/l respectively.
Eight of the patients with side effects were taking an antipsychotic drug concurrently compared with none of those without side effects. A greater proportion of patients with side effects were taking the antinauseant drug thiethylperazine (6/13 v 2/6) and at least one non-steroidal anti-inflammatory drug (10/13 v 2/ 6), whereas a smaller proportion were taking a glucocorticosteroid (3/13 v 4/6). The estimated prevalence ofimportant side effects in the total population of patients receiving palliative treatment in the two units was 2-7-3-6%.
Conclusions -Myoclonus as a side effect of treatment with morphine is more likely to occur in patients taking antidepressant or antipsychotic drugs as antiemetics or as adjuvant agents or non-steroidal anti-inflammatory drugs for additional analgesia. If a patient develops myoclonus the best approach may be to change the supplemental treatment.
Introduction
In patients with advanced malignant disease high doses of opiates may be necessary to relieve pain and thus improve the quality of life. Although doctors recognise that side effects are more probable in patients receiving such treatment long term, there are few reports of those effects. Among the effects are the excitatory responses that have been described for pethidine, which vary from mild nervousness and change of mood to multifocal myoclonus. ' We had gained the impression that these unwanted effects occur with other opiates and are more common than appreciated or reported by either patients or their attendants. The possible roles of precipitating or accompanying factors are not well understood, although norpethidine accumulates in patients receiving high doses of pethidine long term,' particularly in those with renal impairment,' and a possible role of phenothiazines was indicated in a recent study. 3 After one of us (DBR) observed myoclonus in three patients over a short time we studied the occurrence and nature of the more serious side effects in patients receiving high doses of morphine as the primary opiate in their palliative treatment. Table I gives the patients' details and clinical data. All of them (10 men and nine women aged 38-70) had malignant disease and were receiving morphine as the main analgesic: nine subcutaneously through a constant infusion syringe pump and eight orally on a fixed time schedule; the remaining two were studied when the route of administration was changed.
Methods
We collected samples and data over 12 months from patients in the hospice care service or the palliative care unit. Those patients (10) receiving a total daily dose of morphine of at least 500mg orally or 250mg parenterally were enrolled in the study. Other patients (9) were enrolled after an important problem thought to be related to the opiate had been identified. The study was approved by the human rights committee of the University of Western Australia and the ethics committees of the other participating organisations. 12 of the patients, one of whom also had increased sweating. One patient had pronounced hyperalgesia of the skin. The myoclonus was usually described as uncontrollable jerks, affecting the arms (four patients), legs (three), or both arms and legs (five), the duration of the spasms being commonly about one second. The jerks were not symmetrical, and when they occurred in the arms and legs the effect was more apparent in the arms (four patients). Their frequency varied widely among the patients (from once or twice a day to every 10 minutes), and they occurred at different times. The frequency was not related to the overall plasma morphine concentration, but patients related the onset of the jerks and any subsequent increase in their frequency to increases in dose (five patients) or the introduction of the morphine pump or increase in dose (one patient). Jerking occurred during the day and the night; three patients said that it was worse at night and one that it prevented sleep.
The jerking first occurred in one patient (case 16) during the study when an increase in the dose of morphine and a slight increase in her plasma morphine concentration coincided with a reduction in the dose of oxycodone and the introduction of indomethacin and piroxicam. In most of the patients jerking had been present for weeks or months (nine months in one patient (case 1)). Generally, in patients in whom the frequency of jerks was low episodes of jerking had not been seen by doctors or nurses before the study, nor had their presence been mentioned; patients and their relatives had assumed that the jerks were a consequence of the treatment and that they accompanied improved analgesia. As such, many of the patients regarded them as a "small price to pay." Two of the patients, however, said that the jerks were worrying; they prevented one patient sleeping: and three others noted them to be important in that they made them clumsy. In one patient who had had epilepsy induced by trauma (case 16) the myoclonus was separate and distinguishable from her epilepsy.
The plasma morphine concentrations ranged from 39 nmol/l to 3465 nmol/l, the patients receiving daily doses of 120-1200mg morphine orally or 210-800mg by constant infusion syringe pump (table I) . The concentrations were similar in the patients with myoclonus (158-3465 nmol/l, mean 768 nmolIl) and those without myoclonus (39-2821 nmol/l, mean 804 nmol/l). The patient with hyperalgesia (case 19) had a low plasma morphine concentration.
Apart from the total daily dose and plasma concentration of morphine, other factors that were considered as possibly contributing to the myoclonus included the patients' electrolyte concentrations and drugs that they were receiving concurrently. Plasma (table III) . There was also a preponderance of non-steroidal antiinflammatory drugs being taken by the patients with side effects (indomethacin four patients, naproxen two, diclofenac one, piroxicam two, aspirin one, compared with indomethacin one and naproxen one in the patients without myoclonus or hyperalgesia). Two of the patients with side effects were also taking paracetamol, as was one patient who did not have a side effect. Of the six patients who did not have myoclonus or hyperalgesia, four were taking steroids compared with only three of the 13 patients with these side effects. In one of these three patients, who was taking 15 mg prednisolone daily, there was doubt concerning compliance with this drug.
Discussion
Myoclonus as a side effect of long term use of morphine has been assumed to be related to high doses of the drug. Our data, however, show that myoclonus can occur with widely differing plasma morphine concentrations and strongly suggest that drug inte'ractions with morphine contribute. In this study the concurrent use of psychotropic drugs, thiethylperazine (an antiemetic), and potent non-steroidal anti-inflammatory drugs such as indomethacin, was associated with myoclonus, while myoclonus was less common in patients taking corticosteroids. Over halfofthe patients with myoclonus also had predominantly minor abnormalities in plasma electrolyte concentrations.
Of our 19 patients, 13 had an important side effect (a prevalence of 68%); 12 had myoclonus, and several of these had had it for months without reporting or observing it. It is thus an important problem for patients receiving palliative treatment. In the 12 months during which this study was carried out about 1100 patients were cared for by the two palliative care services. As well as the 13 patients reported on here a further eight with myoclonus were studied; in these eight patients the main opiate was pethidine, methadone, or oxycodone, and myoclonus was associated with similar drug and electrolyte patterns to those reported here. We were notified of a further equivalent group of patients, but formal studies were not undertaken usually for logistic reasons. Overall, this gives a conservative estimate of the incidence of myoclonus as a side effect of treatment with an opiate as being 30-40/ 1100 (2 7-3 6%); this is an underestimate, as only some three quarters of all patients would be receiving opiates. Plasma morphine concentrations in the patients in this study reflected the high doses they had taken long term. Single intramuscular injections of morphine (10 mg) give peak plasma concentrations of 180-250 nmol/15 and trough concentrations (after four hours) of about 70 nmol/l. In this study plasma was collected either before a dose was given or from patients receiving a constant infusion, whose measurements can be compared with trough concentrations. Our study did not address side effects such as respiratory depression that occur with sudden raising of plasma morphine concentrations and may occur in patients taking opiates short or long term but was concerned with side effects that present during long term maintenance treatment or attainment of a new steady state. Previous studies of side effects in patients taking opiates long term for analgesia, either postoperatively or in palliative care, have shown that high plasma concentrations of the drugs are important contributing factors. Several of the patients in this study were receiving supplemental opiates (table III) , which would effectively increase their total plasma opiate concentrations. The total analgesic load would be increased further by plasma morphine-6-glucuronide concentrations. Morphine-6-glucuronide, shown recently to be analgesic,6 reaches a concentration four to five times that of morphine during long term treatment with morphine and may be more important in the analgesic effect of the treatment than morphine itself. ' In a study of patients receiving high doses of pethidine long term postoperatively accumulation of norpethidine was accompanied by excitatory side effects'; although renal impairment was directly related to accumulation of norpethidine and the occurrence of side effects, the contribution of disturbances of electrolyte or other drug concentrations was not apparent. In the present study the disturbances in electrolyte concentrations tended to be only mild or moderate and by themselves would probably not have caused the neuromuscular abnormalities. In one patient (case 16) hypokalaemia was probably associated with use of diuretics, but mild abnormalities in electrolyte concentrations, particularly sodium concentrations, are not uncommon in patients with severe disease.8
Our observation that myoclonus and hyperalgesia associated with high doses of morphine may be amplified by, or be part of, a drug interaction is important as the possible interacting agents identified in this study are all important drugs in the treatment of symptoms in modern palliative care. All patients had been receiving fairly large doses of opiates long term to relieve pain and were considered tolerant to morphine. Most of them were also receiving treatment for nausea, and some were receiving adjuvant agents such as psychotropic drugs (including tricyclic antidepressants) or additional analgesics such as non-steroidal anti-inflammatory drugs. Most ofthe patients in whom side effects occurred were receiving more than one drug-for example, of the seven patients taking antidepressants or antipsychotics (all with side effects), five were taking potent non-steroidal anti-inflammatory drugs, four ofwhom were also taking thiethylperazine. While the range of doses of drugs received by patients with and without side effects caused by opiates was not different, the total drug load was greater and the combination apparently critical in those with side effects, some of whom also had abnormal electrolyte BMJ VOLUME 299 15 JULY 1989 concentrations. The apparent protective effect of steroids may be due to the fact that they were taken by patients not receiving other drugs in combination. For instance, myoclonus occurred in three patients taking steroids who were also receiving thiethylperazine and a non-steroidal anti-inflammatory drug. Investigation ofopioids with respect to their receptor pharmacology and neuronal function has concentrated on their primary role, which is analgesia; opiates, however, have a wider influence on spinal function. Their effect on motor neurone function is less well understood than their interaction with the autonomic nervous system, with a adrenergic receptor agonists producing analgesia and antagonists producing hyperalgesia.9 A similar system has been described for serotonin.'°In this study profound hyperalgesia occurred in one patient (case 19) , in whom morphine concentrations were low but who was also taking thiethylperazine and chlorpromazine; both of these drugs can block the a adrenoceptor and serotonin receptor. ' Cerebral secondary tumours cannot be discounted as a cause of or as being related to myoclonus. They are unlikely, however, to be the main cause of all of the cases of myoclonus in our study for the following reasons: symptoms were similar among the patients, the pattern was relatively long and unchanging, and episodes were temporally related to the dose of morphine and route of administration. Also, the epileptiform seizures arising from cerebral secondary tumours generally respond to anticonvulsants.
If our patients are representative it may be possible to treat myoclonus by changing palliative treatment. Reducing the total daily dose of opiate may reduce or stop the myoclonus: several of the patients related the onset of myoclonus and any subsequent loss of symptoms to increases or decreases in the dose of opiate. Overall, however, reducing the dose may have limited success in the light of the wide range of plasma concentrations over which myoclonus occurred. Ideally, it seems that psychotropic drugs should be stopped if possible; we are planning a trial to test this theory. Alternative antinauseant or adjuvant drugs could be used: domperidone is considered not to cross the blood-brain barrier,'9 although it was taken as the only antiemetic by one of the patients with myoclonus (case 12), or alternatively steroids could be used as adjuvant agents20 rather than phenothiazines. Potent non-steroidal anti-inflammatory drugs could be reserved for patients with bony secondary tumours or with another clinical indication such as inflammatory joint disease: the onset ofmyoclonus was clearly related to the introduction of indomethacin or piroxicam in one of the patients. In our experience, anticonvulsants and baclofen are unsuccessful in controlling myoclonus. Frenk 
